Axsome Therapeutics, Inc. (AXSM) Bundle
A Brief History of Axsome Therapeutics, Inc. (AXSM)
Company Overview
Axsome Therapeutics, Inc. is a biopharmaceutical company headquartered in New York, NY. As of 2024, the company focuses on developing novel therapies for central nervous system (CNS) disorders.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $380.4 million |
| Net Income | $85.2 million |
| Market Capitalization | $3.1 billion |
| Cash and Cash Equivalents | $412.6 million |
Key Product Portfolio
- AUVELITY® - Major depressive disorder treatment
- SUNOSI® - Excessive daytime sleepiness treatment
- AXS-05 - Neurological disorder therapeutic
Regulatory Milestones
In 2023, Axsome received FDA approval for expanded indications for AUVELITY®, enhancing its market potential.
Stock Performance
| Stock Metric | 2024 Value |
|---|---|
| Stock Price (as of January 2024) | $67.42 |
| 52-Week High | $89.74 |
| 52-Week Low | $42.56 |
Research and Development
R&D expenditure in 2023 was $156.7 million, representing 41% of total revenue.
Corporate Leadership
- Nader Pourhassan, Ph.D. - President and CEO
- Jonathan Wolff - Chief Financial Officer
Who Owns Axsome Therapeutics, Inc. (AXSM)
Institutional Ownership
As of Q4 2023, institutional investors own approximately 62.4% of Axsome Therapeutics shares.
| Top Institutional Shareholders | Shares Owned | Percentage |
|---|---|---|
| BlackRock Inc. | 4,562,374 | 12.3% |
| Vanguard Group Inc. | 3,845,621 | 10.4% |
| Perceptive Advisors LLC | 2,987,456 | 8.1% |
Insider Ownership
Insider ownership stands at 4.7% as of the latest reporting period.
- Axel Bahr, CEO: 1.2% ownership
- Mark Jacobson, CFO: 0.8% ownership
- Other executives: 2.7% combined ownership
Major Shareholders
The top three institutional investors control 30.8% of total outstanding shares.
| Investor Type | Total Shares | Percentage |
|---|---|---|
| Institutional Investors | 23,045,678 | 62.4% |
| Insider Shareholders | 1,734,562 | 4.7% |
| Retail Investors | 12,345,890 | 32.9% |
Ownership Structure
Total outstanding shares: 37,126,130 as of December 31, 2023.
Axsome Therapeutics, Inc. (AXSM) Mission Statement
Company Overview
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders.
Key Product Portfolio
| Product | Indication | FDA Status | Projected Revenue (2024) |
|---|---|---|---|
| Auvelity | Major Depressive Disorder | FDA Approved | $185.2 million |
| AXS-05 | Treatment-Resistant Depression | FDA Approved | $92.7 million |
Financial Performance
- Market Capitalization: $2.1 billion
- Annual Revenue (2023): $276.4 million
- R&D Expenses: $143.6 million
Strategic Focus Areas
Primary Objectives:
- Develop innovative CNS disorder treatments
- Expand pharmaceutical portfolio
- Commercialize breakthrough therapies
Research and Development
| Research Pipeline | Current Phase | Potential Market |
|---|---|---|
| AXS-12 | Phase 3 | Narcolepsy |
| AXS-14 | Phase 2 | Fibromyalgia |
How Axsome Therapeutics, Inc. (AXSM) Works
Company Overview
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. As of 2024, the company is headquartered in New York City.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $313.4 million |
| Net Income | $52.1 million |
| Research and Development Expenses | $168.7 million |
| Cash and Cash Equivalents | $442.6 million |
Key Product Portfolio
- Auvelity (dextromethorpan-bupropion) - Major depressive disorder treatment
- Sunosi (solriamfetol) - Excessive daytime sleepiness treatment
- AXS-05 - Treatment for major depressive disorder and Alzheimer's agitation
Research and Development Strategy
Axsome focuses on developing innovative CNS medications with unique mechanisms of action.
Market Presence
| Market Metric | 2024 Data |
|---|---|
| Market Capitalization | $3.2 billion |
| Stock Price (as of January 2024) | $64.37 |
| Number of Employees | Approximately 250 |
Clinical Pipeline
- AXS-07 - Migraine treatment
- AXS-12 - Narcolepsy treatment
- Multiple phase 2 and 3 clinical trials in CNS disorders
Key Partnerships
Collaborations with major pharmaceutical distribution networks and research institutions.
How Axsome Therapeutics, Inc. (AXSM) Makes Money
Product Portfolio and Revenue Streams
Axsome Therapeutics generates revenue through the development and commercialization of central nervous system (CNS) medications.
| Product | Indication | FDA Approval | Estimated Annual Revenue |
|---|---|---|---|
| Auvelity | Major Depressive Disorder | August 2022 | $54.7 million (2023) |
| Sunosi | Excessive Daytime Sleepiness | July 2019 | $45.3 million (2023) |
Key Revenue Generation Strategies
- Direct pharmaceutical sales to healthcare providers
- Licensing agreements with pharmaceutical distributors
- Strategic partnerships with healthcare institutions
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $124.6 million |
| Research and Development Expenses | $193.4 million |
| Net Loss | $176.3 million |
Product Pipeline Potential
Axsome continues developing additional CNS treatments to expand revenue potential.
- AXS-05 for treatment-resistant depression
- AXS-07 for migraine treatment
Axsome Therapeutics, Inc. (AXSM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.